Endocrine Abstracts

Contents

• Androgens Biannual Meeting 2016
• • Invited Lectures
  • • Determinants and clinical correlates of androgen exposure: phases of life and disease

      ea0042il1
    • Neuro-inflammatory origins of the sexual differentiation of the brain

      ea0042il2
  • Androgen Receptor
  • • Three-dimensional structure of homodimeric androgen receptor ligand-binding domain

      ea0042il3
    • Modulation of androgen receptor signaling in prostate cancer cells by SUMOylation and NFκB pathways

      ea0042il4
  • Methods and Techniques
  • • Droplet Digital PCR: Resolving difficult challenges in nucleic acid detection and quantitation

      ea0042il5
  • Hormone and Disease
  • • Androgens and cardiovascular diseases

      ea0042il6
    • Effects of long-term testosterone therapy on obesity, glycaemic control and other features of the metabolic syndrome

      ea0042il7
  • Androgen Receptor and Chromatin
  • • The Androgen Receptor chromatin landscape in prostate tumors: biomarker discovery and beyond

      ea0042il8
  • Metabolism in Prostate Cancer
  • • Regulating androgen action by steroid synthesis and metabolism

      ea0042il9
    • Causes and consequences of metabolic changes in prostate tumours

      ea0042il10
  • Castration Resistant Prostate Cancer
  • • Determinants and clinical correlates of androgen exposure: phases of life and disease

      ea0042il1
    • Identifying drivers of disease progression to personalize prostate cancer therapy

      ea0042il12
  • Androgen Receptor in Castration Resistant Prostate Cancer
  • • Androgen receptor: master contortionist in prostate cancer

      ea0042il13
  • Genetics, Genomics and Epigenetics
  • • Genomic and epigenomic patterns in prostate cancer

      ea0042il14
    • The genetics of prostate cancer specific events

      ea0042il15
• Oral Communications
• • (1)
  • • Non-classical testosterone signaling in the testis

      ea0042oc1
    • Control of androgen bioactivity by sex hormone-binding globulin

      ea0042oc2
    • Novel trifluoromethylated enobosarm analogues show very potent antiandrogen activity in prostate cancer cells, and cells with acquired bicalutamide resistance whilst maintaining tissue selectivity in vivo

      ea0042oc3
    • The use of apolipoprotein D as a biomarker for androgen sensitivity identifies a new type of androgen insensitivity syndrome that is not associated with a mutation in the androgen receptor gene

      ea0042oc4
    • What is the impact of AR modulation in the decidualisation of hESCs from women with endometriosis?

      ea0042oc5
    • Transgender: biological model for steroid action

      ea0042oc6
    • Identification of AR genomic targets in mesenchymal cell subsets during prostate development

      ea0042oc7
    • Fibroblast AR signalling in prostate cancer: Unique regulation of AR signalling, and associations with patient outcomes by influencing cancer progression and invasion

      ea0042oc8
    • Chromatin relaxation is a feature of advanced prostate cancer

      ea0042oc9
    • Glycosylation is a global target for androgen control in prostate cancer cells

      ea0042oc10
    • Sex steroid deficiency alters renal calcium transporter expression independently of its effect on bone resorption

      ea0042oc11
    • Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC)

      ea0042oc12
    • The role of nuclear steroid receptors in castration-resistant prostate cancer (CRPC)

      ea0042oc13
    • Optimization of an engineered microrepressor for the treatment of castration-resistant prostate cancer

      ea0042oc14
    • In vivo imaging reveals prostate pathology in the PTEN knockout murine model of prostate cancer

      ea0042oc15
    • Genomic analysis of Enzalutamide-resistant cells

      ea0042oc16
    • miR-32 promotes replicative changes in prostate epithelium in vivo

      ea0042oc17
• Poster Presentations
• • (1)
  • • Inhibition of NADPH oxidase 4 attenuates stromal activation associated with prostate cancer

      ea0042p1
    • Functional analysis of the AR LBD dimerization surface

      ea0042p2
    • Diminished response of prostate cancer cells to antiandrogens upon co-culture with cancer-associated fibroblasts as shown in a 3-dimensional prostate cancer epithelial-stromal organoid model

      ea0042p3
    • Expression of a novel androgen-regulated long noncoding RNA correlates with progression-free survival in prostate cancer patients

      ea0042p4
    • Androgen pathway regulating microRNAs in prostate cancer progression and therapy

      ea0042p5
    • The bi-directional interaction of AR and IL6 signalling in the response to enzalutamide in prostate cancer cells

      ea0042p6
    • μ-Crystalline as hormone antagonist in prostate cancer

      ea0042p7
    • Antiandrogens reduce intratumoral androgen concentrations and induce androgen receptor expression in castration-resistant VCaP xenografts

      ea0042p8
    • The deubiquitinating enzyme USP12 controls prostate cancer cell survival by regulating the AR-AKT-p53 signalling network

      ea0042p9
    • Metastases-prone localized prostate cancer: a genomic analysis

      ea0042p10
    • Switch to succinate-mediated mitochondrial respiration associated with HIF-1[alpha] stabilization in PTEN negative prostate cancer cells

      ea0042p11
    • Exploiting pioneer factors of androgen receptor variants for novel prostate cancer therapies

      ea0042p12
    • Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer

      ea0042p13
    • Androgen receptor variants and microenvironment in prostate cancer

      ea0042p14
    • Altered steroid profiles in prostate cancer xenograft model with low ADRB2 levels

      ea0042p15
    • Identification of protein kinases involved in AR transcriptional regulation in prostate cancer

      ea0042p16
    • Next generation sequencing panels to predict response to hormonal therapy in prostate cancer

      ea0042p17
    • Altering androgen precursor availability impacts on endometrial function

      ea0042p18
    • The AR/NCOA1 signaling regulates prostate cancer migration by involvement of PRKD1

      ea0042p19
    • Combined AR phosphorylation at serine 81 and serine 213 are associated with decreased survival in Castrate Resistant Prostate Cancer

      ea0042p20
    • Investigating the role of SUMOylation of androgen receptor splice variants by SUMO1 in castration resistant prostate cancer

      ea0042p21
    • The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells

      ea0042p22
    • Characterising mechanisms of aberrant androgen receptor signalling in advanced prostate cancer

      ea0042p23
    • Identification and characterization of a CRM1/XPO1-dependent nuclear export signal in the human androgen receptor

      ea0042p24
    • Mitochondrial function and mitochondrial heteroplasmy levels differ between benign and malignant prostate tissue.

      ea0042p25
    • Mechanisms behind tumor relapse in 22Rv1 xenografts after treatment with abiraterone or cabazitaxel

      ea0042p26
    • The amino terminal domain of steroid hormone receptors as a novel drug target: Identification of small molecule inhibitors

      ea0042p27
    • Evidence for neuroendocrine progenitor cells in a transgene mouse model of prostate cancer

      ea0042p28
    • Potential of Metabolome Analysis for new Insights into System Biology and Relevance for Translational Medicine

      ea0042p29
    • Critical Role of Androgen Receptor Level in Prostate Cancer Cell Resistance to New Generation Antiandrogen Enzalutamide

      ea0042p30
    • Mediators of stress resistance in prostate cancer cells

      ea0042p31
    • Differential expression and androgen regulation of microRNA molecules in breast cancer cells

      ea0042p32
    • Phosphorylation of androgen receptor at serine 81 by cyclin-dependent kinases

      ea0042p33
    • Mechanisms of radioresistance in prostate cells

      ea0042p34
    • Isolation, propagation and characterisation of primary prostate cancer epithelial cell lines from prostate specimens

      ea0042p35
    • Androgen and Estrogen Receptor Co-regulation of Human UDP-glucuronosyltransferases 2B15 and 2B17 in Breast Cancer

      ea0042p36
    • Abstract unavailable

      ea0042p37
    • Histological modeling of prostate cancer

      ea0042p38
    • Androgen receptor variant 7 induces cellular senescence

      ea0042p39
    • Segment-specific enrichment of AP-2 and Runx motifs within caput- and IS-preferred androgen receptor binding sites in the mouse epididymis

      ea0042p40
    • Characterisation of Androgen and Estrogen Receptor Cross-Talk

      ea0042p41
    • High levels of the AR-V7 splice variant and co-amplification of the Golgi protein coding YIPF6 in AR amplified prostate cancer bone metastases

      ea0042p42